Specifically, NAMPT is the rate-limiting enzyme of the NAD+ salvage pathway in mammals and increases in its expression/activity play key roles in melanoma therapeutic resistance to BRAF/MEKi [7, 23]. This evidence concerns the gene BRAF and melanoma.